ClinicalTrials.gg
Active, not recruitingNCT05141682Updated Oct 21, 2026

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

A Phase 1/2 interventional study of Oral Azacitidine in T-Cell Large Granular Lymphocyte Leukemia, sponsored by Jonathan Brammer. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Jonathan Brammer · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 21, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies in Leukemia, Large Granular Lymphocytic with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Leukemia, Large Granular Lymphocytic · United States.

Enrollment
67th of 86
11 · median 30
Started
2022
with 3 others
Phase 1/2
11 of 113
1 open now
Primary completion
2026-02
later than 3 of 11 live
Registered
106th of 113
by date

Among the 113 studies in Leukemia, Large Granular Lymphocytic with a site in United States, this one is the 67th largest by enrollment of the 86 interventional ones that give a count, is one of 4 that started in 2022, is one of 11 in phase 1/2, reaches primary completion later than 3 of the 11 other live ones, and was the 106th registered.

Leukemia, Large Granular Lymphocytic

144 studies on the registry are indexed under Leukemia, Large Granular Lymphocytic; 19 are open to participants now.

Browse Leukemia, Large Granular Lymphocytic studies →

Open to participants now

7 of the 113 studies in Leukemia, Large Granular Lymphocytic with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Leukemia, Large Granular Lymphocytic studies recruiting now, 13 (76%) set no upper age limit and 3 (18%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Leukemia, Large Granular Lymphocytic with a site in United States, or all of them as a file.
02

Study summary

This phase I/II trial studies the best dose, possible benefits and/or side effects of oral azacitidine in treating patients with T-cell large granular lymphocytic leukemia that has come back (relapsed) or has not responded to previous treatment (refractory). Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the safety and maximum tolerated dose (MTD) of oral azacitidine (CC-486) in patients with symptomatic T-cell large granular lymphocytic leukemia (T-LGLL). (Phase I) II. To determine the overall response rate (complete response [CR] and partial response [PR]) of CC-486 in patients with T-LGLL. (Phase II)

SECONDARY OBJECTIVES:

I. Duration of response to CC-486. II. Progression-free survival. III. Rate of conversion from PR at 4 months to CR at 8 and 12 months. IV. Rate of molecular remission (T-cell receptor [TCR] clearance, STAT3 mutation clearance) at 4, 8, 12 months.

V. Effect of treatment on IL-15 promoter demethylation. VI. Effect of CC-486 on IL-15 promoter demethylation. VII. Safety of CC-486 in T-LGLL patients.

OUTLINE: This is a dose-escalation study.

Patients receive azacitidine orally (PO) on days 1-14. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with PR or CR continue treatment for up to 8 additional cycles in the absence of disease progression or unacceptable toxicity.

03

Conditions studied

  • T-Cell Large Granular Lymphocyte Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older
  • Diagnosis of T-LGLL defined as: CD3+CD8+ cell population > 650/mm\^3 and the presence of a clonal T-cell receptor (within 1 month of diagnosis). This also includes patients with rare T-LGLL variants include CD4+ T-LGLL, and gamma/delta T-LGLL which can be CD4- and CD8, though patients still must have an LGL cell population >500 cells/mm3 and the presence of a clonal T-cell receptor within 1 month of diagnosis or relapse. Note: patients with myelodysplastic syndrome (MDS)-like T-LGLL may be included with principal investigator (PI) approval even if CD3+CD8+ cell population is \< 650/mm\^3, though +TCR is required. Natural-killer (NK) large granular lymphocytic leukemia (LGL) is also permitted, provided there is a clonal NK-cell population noted with > 500 cells/mm\^3
  • Failed at least one line of frontline therapy; off treatment for at least 14 days or 5 half-lives, whichever is longer
  • Require Treatment for T-LGLL (One or more required)

    • Symptomatic anemia with \< 10 g/dL
    • Transfusion-dependent anemia
    • Neutropenia with (ANC) \< 500/mm\^3
    • Neutropenia with ANC \< 1500/mm\^3 with recurrent infections
  • count >= 50 x 10\^9/L
  • Serum creatinine =\< 2 x the (ULN)
  • Total =\< 1.5 x ULN (patients with Gilbert's syndrome with a bilirubin > 1.5 x ULN permitted)
  • (AST) and alanine aminotransferase (ALT) =\< 1.5 x ULN
  • (ECOG) performance status =\< 2
  • Men and women of must agree to follow accepted methods for the duration of the study. Female subject is either or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study
  • Able to sign

Exclusion criteria

Exclusion Criteria:

  • Active Infection requiring ongoing anti-microbial treatment. Patients with (HIV), positive surface antigen or antibody will be excluded
  • Concurrent immune-suppressive therapy (prednisone or equivalent up to 20 mg permitted to treat T-LGL symptoms, but must be weaned within one month of initiation of trial drug). Patients on stable, chronic prednisone =\< 10 mg for rheumatologic/ conditions are exempted from this requirement. They may enroll on the study
  • Active, concurrent unless deemed related to T-LGLL by PI
  • Prior use of 5-azacytidine or decitabine
  • Positive pregnancy test
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Treatment (Oral Azacitidne)

    Patients will receive CC-486 orally (PO) D1-14 of a 28-day cycle, in a similar fashion to the QUAZAR study for a minimum of 4 cycles. Patients that achieve a response (CR or PR) will remain on study for a maximum of 12 months. Patients without a response at 4 months will come off the study.

    Drug: Oral Azacitidine

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose of oral azacitidine (CC-486) (Phase I)

    Time frame: Up to 4 cycles (1 cycle = 28 days)

  2. Overall response rate (complete response [CR] + partial response [PR]) (Phase II)

    Assessed by the investigator based upon criteria derived from the ECOG 5998 and BNZ-1 clinical trials.

    Time frame: Up to 3 years

Secondary outcomes

  1. Duration of response to CC-486

    Time frame: Up to 3 years

  2. Progression-free survival (PFS

    Time frame: Up to 3 years

  3. Rate of conversion from PR at 4 months to CR at 8 months

    Time frame: From 4 months to 8 months

  4. Rate of conversion from PR at 4 months to CR at 12 months

    Time frame: From 4 months to 12 months

  5. Rate of molecular remission (T-cell receptor [TCR] clearance, STAT3 mutation clearance)

    Time frame: At 4 months

  6. Rate of molecular remission (TCR clearance, STAT3 mutation clearance)

    Time frame: At 8 months

  7. Rate of molecular remission (TCR clearance, STAT3 mutation clearance)

    Time frame: At 12 months

  8. Rate of treatment-emergent adverse events

    Time frame: Up to 12 months

  9. Degree of IL-15 promoter demethylation in responders versus non-responders

    Time frame: Up to 3 years

07

Study locations

2 sites
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2022 to primary completion in Feb 2026, 43 months.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2021
First posted
Dec 2, 2021
StartActual
Jun 29, 2022
Primary completionActual
Feb 19, 2026
CompletionEst.
Jan 30, 2027was Sep 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Sep 30, 2026→Jan 30, 2027
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Study completion Sep 30, 2026→Jan 30, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05141682
Lead sponsor
Jonathan Brammer
Responsible party
Jonathan Brammer (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Sponsor-investigator
First posted
Dec 2, 2021
Start date
Jun 29, 2022
Primary completion
Feb 19, 2026
Completion
Jan 30, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Jonathan Brammer, MD
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cc-486

Start the discussion